2. Search Result
Search Result
Results for "

39

" in MedChemExpress (MCE) Product Catalog:

642

Inhibitors & Agonists

3

Fluorescent Dye

1

Biochemical Assay Reagents

61

Peptides

3

Inhibitory Antibodies

56

Natural
Products

70

Recombinant Proteins

29

Isotope-Labeled Compounds

24

Antibodies

2

Click Chemistry

44

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14462
    NP118809

    39-1B4

    		 Calcium Channel Cardiovascular Disease
    NP118809 is a potent N-type calcium channel blocker, with an IC50 of 0.11 μM; also less potently inhibits L-type calcium channel with an IC50 of 12.2 μM.
    NP118809
  • HY-137011
    3,9-Dihydroeucomin

    		COX Others
    3,9-Dihydroeucomin (compound 12) is a natural homoisoflavonoid compound with less COX-2 inhibitory activitys .
    3,9-Dihydroeucomin
  • HY-W067091
    3-((((9H-Fluoren-9-yl)methoxy)carbonyl)(methyl)amino)propanoic acid

    		Amino Acid Derivatives Others
    3-((((9H-Fluoren-9-yl)methoxy)carbonyl)(methyl)amino)propanoic acid is an alanine derivative .
    3-((((9H-Fluoren-9-yl)methoxy)carbonyl)(methyl)amino)propanoic acid
  • HY-P1603
    ACTH (22-39)

    Adrenocorticotropic Hormone (22-39)

    		 Melanocortin Receptor Metabolic Disease
    ACTH (22-39) is an adrenocorticotropic hormone (ACTH) fragment. ACTH (22-39) is the 22-39 sequence of ACTH.
    ACTH (22-39)
  • HY-141659
    CMPD-39
    2 Publications Verification

    		 Deubiquitinase Cancer
    CMPD-39 is a selective USP30 inhibitor with an IC50 of 0.02 μM. CMPD-39 increases protein ubiquitination and accelerates mitophagy .
    CMPD-39
  • HY-103308
    TRAM-39

    		Potassium Channel Neurological Disease
    TRAM-39 is a selective blocker of intermediate conductance Ca2+-activated K+ (IKCa) channels. TRAM-39 inhibits KCa3.1 channel with an IC50 value of 60 nM. TRAM-39 can be used for the research of ataxia, epilepsy, memory disorders, schizophrenia and Parkinson’s disease .
    TRAM-39
  • HY-N8762
    3,9-Dihydroxypterocarpan

    Demethylmedicarpin

    		 Bacterial Others
    3,9-Dihydroxypterocarpan (Demethylmedicarpin) is a Steroids product that can be isolated from the herbs of Nerium indicum Mill. .
    3,9-Dihydroxypterocarpan
  • HY-168912
    3,9-Diazaspiro[5.5]undecane-3-carboxylic acid

    		PROTAC Linkers Cancer
    3,9-Diazaspiro[5.5]undecane-3-carboxylic acid is the linker that can be used for synthesis of PROTAC c-Met degrader-3 (HY-168910) .
    3,9-Diazaspiro[5.5]undecane-3-carboxylic acid
  • HY-146364
    CI-39

    		HIV Infection
    CI-39 is an antiviral natural product. CI-39 is an NNRTI (non-nucleoside reverse transcriptase inhibit) antiviral agent with an EC50 of 3.40 µM and an CC50 of >30 µM for wild type HIV-1. CI-39 inhibits HIV-1 RT DNA polymerase and ribonuclease H activitiessup .
    CI-39
  • HY-149473
    AChE-IN-39

    		Cholinesterase (ChE) Neurological Disease
    AChE-IN-39 (Compound 7c) is an AChE inhibitor (IC50: 0.058 μM). AChE-IN-39 has DPPH scavenging activity. AChE-IN-39 improves the cognitive impairment in AlCl3-induced amnesia animal model. AChE-IN-39 can be used for research of Alzheimer's disease .
    AChE-IN-39
  • HY-P1259
    PR-39

    		Proteasome Bacterial Inflammation/Immunology
    PR-39, a natural proline- and arginine-rich antibacterial peptide, is a noncompetitive, reversible and allosteric proteasome inhibitor. PR-39 reversibly binds to the α7 subunit of the proteasome and blocks degradation of NF-κB inhibitor IκBα by the ubiquitin-proteasome pathway. PR-39 stimulates angiogenesis, inhibits inflammatory responses and significant reduces myocardial infarct size in mice .
    PR-39
  • HY-162325
    WJ-39

    		Aldose Reductase Mitochondrial Metabolism Apoptosis Mitophagy Metabolic Disease
    WJ-39 is an orally active aldose reductase (AR) inhibitor. WJ-39 improves tubular damage in diabetic nephropathy rats by activating PINK1/Parkin signaling, promoting mitophagy, and attenuating apoptosis .
    WJ-39
  • HY-108678
    TC OT 39

    		Oxytocin Receptor Vasopressin Receptor Neurological Disease
    TC OT 39 is a synthetic oxytocin analog, as well as a selective agonist of oxytocin receptor (OXTR, EC50=180 nM). TC OT 39 is also an Avprla vasopressin receptor antagonist with an Ki value of 330 nM. TC OT 39 exhibits sedative effects in mouse models .
    TC OT 39
  • HY-P5672
    Maximin 39

    		Bacterial Infection
    Maximin 39 is an antimicrobial peptide derived from the toad brain. Maximin 39 is active against Staphylococcus aureus and Escherichia coli, with MIC values of 18.8, 37.5 μg/mL, respectively .
    Maximin 39
  • HY-155190
    Antitubercular agent-39

    		Bacterial Infection
    Antitubercular agent-39 (Compound P1) is a potent antitubercular agent. Antitubercular agent-39 is active against drug-resistant strains and drug-susceptible clinical isolates. Antitubercular agent-39 inhibits Mtb strain H37Rv with a MIC less than 1 μM .
    Antitubercular agent-39
  • HY-144056
    EGFR-IN-39

    		EGFR Cancer
    EGFR-IN-39 is a potent inhibitor of EGFR. EGFR-IN-39 is an anti-tumor agent with low toxic side effects. EGFR-IN-39 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-39 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 2) .
    EGFR-IN-39
  • HY-146392
    HDAC-IN-39

    		HDAC Microtubule/Tubulin Apoptosis Cancer
    HDAC-IN-39 (compound 16c) is a potent HDAC inhibitor, with IC50 values of 1.07 μM (HDAC1), 1.47 μM (HDAC2), and 2.27 μM (HDAC3), respectively. HDAC-IN-39 also significantly inhibits microtubule polymerization. HDAC-IN-39 induces cell cycle arrest at the G2/M phase. HDAC-IN-39 displays promising anticancer activity against resistant cancer cells .
    HDAC-IN-39
  • HY-151982
    Tubulin polymerization-IN-39

    		Microtubule/Tubulin Cardiovascular Disease Cancer
    Tubulin polymerization-IN-39 is a tubulin polymerization inhibitor (IC50: 4.9 μM). Tubulin polymerization-IN-39 occupies the colchicine-binding site. Tubulin polymerization-IN-39 inhibits cancer cell proliferation .
    Tubulin polymerization-IN-39
  • HY-156703S
    HBV-IN-39-d3

    		HBV Infection
    HBV-IN-39-d3 (Example 14) is a deuterated HBV-IN-39 (Example 13). HBV-IN-39 is an HBV inhibitor. HBV-IN-39-d3 has better oral bioavailability than HBV-IN-39 .
    HBV-IN-39-d3
  • HY-170887
    MAO-B-IN-39

    		Keap1-Nrf2 Monoamine Oxidase Inflammation/Immunology
    MAO-B-IN-39 (compound11) is a selective monoamine oxidase B (MAO-B) inhibitor. MAO-B-IN-39 inhibits MAO-Bwith an IC50 of 3.61 μM. MAO-B-IN-39 demonstrates a potent NRF2 induction capacity. MAO-B-IN-39 exhibits potent anti-inflammatory and neuroprotective activity in OS (oxidative stress)-related in vitro models. MAO-B-IN-39 demonstrates high liver microsomal stability and favorable pharmacokinetics in mice. MAO-B-IN-39 is potential for Parkinson’s disease (PD) research .
    MAO-B-IN-39
  • HY-168664
    CPD-39

    		PROTACs CDK Cancer
    CPD-39 is a potent and orally active CCND1 and CDK4 heterobifunctional PROTAC degrader. CPD-39 shows anti-proliferation. (Pink: ligand for target protein (HY-50767); black: linker (HY-20240); Blue: E3 ligase ligand (HY-168667)) .
    CPD-39
  • HY-149520
    HPK1-IN-39

    		MAP4K Cancer
    HPK1-IN-39 (Compound 10n) is a selective HPK1 Inhibitor (IC50: 29 nM). HPK1-IN-39 inhibits the phosphorylation of SLP76. HPK1-IN-39 can be used for research of cancer immunotherapy .
    HPK1-IN-39
  • HY-172095
    BRD4 Inhibitor-39

    		Epigenetic Reader Domain Apoptosis Cancer
    BRD4 Inhibitor-39 (compound 12m) is an orally available BRD4 inhibitor with an IC50 value of 0.02 μM. BRD4 Inhibitor-39 induces apoptosis. BRD4 Inhibitor-39 has anti-tumor activity .
    BRD4 Inhibitor-39
  • HY-19732
    BIBS 39

    		Angiotensin Receptor Cardiovascular Disease Endocrinology
    BIBS 39 is a new nonpeptide angiotensin II (AII) receptor antagonist.
    BIBS 39
  • HY-P1259A
    PR-39 TFA

    		Proteasome Bacterial Inflammation/Immunology
    PR-39 TFA, a natural proline- and arginine-rich antibacterial peptide, is a noncompetitive, reversible and allosteric proteasome inhibitor. PR-39 TFAreversibly binds to the α7 subunit of the proteasome and blocks degradation of NF-κB inhibitor IκBα by the ubiquitin-proteasome pathway. PR-39 TFA stimulates angiogenesis, inhibits inflammatory responses and significant reduces myocardial infarct size in mice .
    PR-39 TFA
  • HY-170993
    Antimicrobial agent-39

    		Antibiotic Bacterial Infection Inflammation/Immunology
    Antimicrobial agent-39 (Compound 8i) is an antibiotic that targets 50S ribosomal subunit and inhibits bacterial protein synthesis. Antimicrobial agent-39 disrupts bacterial cell membranes, leads to leakage of cell contents, thereby exhibiting board-spectrum actibacterial activity. Antimicrobial agent-39 targets organic cation transporters (OCTs), accumulates in infected kidneys, thereby ameliorating pyelonephritis in mouse models .
    Antimicrobial agent-39
  • HY-120951
    PFM39

    		Endonuclease Cancer
    PFM39, a Mirin analog, is a potent and selective MRE11 exonuclease inhibitor. PFM39 inhibits phosphate rotation for dsDNA exonuclease activity. PFM39 does not inhibit TmMre11 or human MRE11/MRN endonuclease activity .
    PFM39
  • HY-129314
    CM-39

    		Aldehyde Dehydrogenase (ALDH) Cancer
    CM-39 is a non-covalent and reversible inhibitor for aldehyde dehydrogenase 1A (ALDH1A) with an IC50 of 0.9 μM .
    CM-39
  • HY-116681
    Aflavarin

    		Insecticide Infection
    Aflavarin is produced from cluster 39 expressed mainly in sclerotia. Aflavarin exhibits anti-insectan activity .
    Aflavarin
  • HY-160259
    VEGFR-2-IN-39

    		PROTACs VEGFR Cardiovascular Disease
    VEGFR-2-IN-39 (PROTAC-5) is a PROTAC targeting VEGFR-2 (IC50: 208.6 nM). VEGFR-2-IN-39 has low toxicity.VEGFR-2-IN-39 inhibits the proliferation of EA.hy926, one of HUVECs, in a concentration-dependent manner, with an IC50 of 38.65 µM .
    VEGFR-2-IN-39
  • HY-170389
    BChE-IN-39

    		Cholinesterase (ChE) Neurological Disease
    BChE-IN-39 (Compound 7c) is a selective inhibitor for butyrylcholinesterase (BChE) with an IC50 of 0.08 μM (IC50=3.98 μM for AChE). BChE-IN-39 downregulates the GSK-3β expression, inhibits the hyperphosphorylation of tau protein .
    BChE-IN-39
  • HY-126124
    AP39
    5 Publications Verification

    		 Reactive Oxygen Species Cardiovascular Disease Neurological Disease
    AP39 is a triphenylphosphonium derivatised anethole dithiolethione and mitochondria-targeting hydrogen sulfide (H2S) donor. AP39 increases intracellular H2S levels. AP39 exerts cytoprotective effects and maintains mitochondrial DNA integrity under oxidative stress conditions. AP39 protects against myocardial reperfusion injury in mice model and has the potential for Alzheimer's disease research .
    AP39
  • HY-172170
    LSD1-IN-39

    		Histone Demethylase Cancer
    LSD1-IN-39 (Compound 14) is a reversible inhibitor for LSD1 with an IC50 of 0.18 μM. LSD1-IN-39 exhibits broad-spectrum anti-proliferative activity against cancer cells, inhibits the cell migration of HepG2 and inhibits the epithelial-mesenchymal transition. LSD1-IN-39 exhibits antitumor activity in mouse models .
    LSD1-IN-39
  • HY-W131282
    Antimalarial agent 39

    		Parasite Infection
    Antimalarial agent 39 (compound 1) is an intermediate in the synthesis of antimalarial agents .
    Antimalarial agent 39
  • HY-157107
    ICMT-IN-39

    		ICMT Cancer
    ICMT-IN-39 (compound 18) is an inhibitor of ICMT (IC50=0.031 μM) .
    ICMT-IN-39
  • HY-170910
    Hsp90-IN-39

    		HSP Cancer
    Hsp90-IN-39 (Compound 16t) is a HSP90 inhibitor with notable selectivity for the HSP90α isoform. Hsp90-IN-39 demonstrates significant antiproliferative activity in various cancer cell lines, including MCF-7, HCT116, SKBr3, K562, and A549. Hsp90-IN-39 holds potential for cancer research .
    Hsp90-IN-39
  • HY-150536
    EP39

    		HIV HIV Protease Infection
    EP39 is a potent HIV-1 maturation inhibitor. EP39 interacts with the SP1 domain of Gag. EP39 decreases the dynamics of CA-SP1 junction, by binding to the QVT motif of the SP1 domain, and perturbs the natural coil-helix equilibrium on both sides of the SP1 domain by stabilizing the transient alpha helical structure. EP39 acts by arresting maturation of HIV-1 thereby blocking its infectivity .
    EP39
  • HY-170723
    JAK-IN-39

    		JAK TNF Receptor Infection Inflammation/Immunology
    JAK-IN-39 (compound 11) is a JAK inhibitor that suppresses JAK1, JAK2, JAK3 with IC50 values of 0.05, 1.18, and 0.03 nM, respectively. JAK-IN-39 can inhibit the viability of TF-1 cells and also suppress the production of lymphocyte TNFα and INFγ in vitro .
    JAK-IN-39
  • HY-147723
    HIV-1 inhibitor-39

    		HIV Infection
    HIV-1 inhibitor-39 (compound 3c) is a potent HIV-1 inhibitor with an EC50 of >112.88 µM. HIV-1 inhibitor-39 shows anti-RT (HIV-1 reverse transcriptase) activities with an IC50 of 15.75 µM. HIV-1 inhibitor-39 shows cytotoxicity for MT-4 cells with an CC50 of 112.9 µM .
    HIV-1 inhibitor-39
  • HY-157582
    MS39N

    		EGFR Others
    MS39N (compound 27) is a negative control for MS39 that binds EGFR without inducing degradation .
    MS39N
  • HY-151423
    Antifungal agent 39

    		Fungal Infection
    Antifungal agent 39 (Compound 9h) is a broad-spectrum antifungal agent .
    Antifungal agent 39
  • HY-P10526
    CRAMP (1-39)

    		Bacterial Infection
    CRAMP (1-39) is an antimicrobial peptide. CRAMP (1-39) has shown potent bactericidal effects against multiple strains of Neisseria meningitidis in vitro. CRAMP (1-39) can be used to study drug-resistant bacterial infections .
    CRAMP (1-39)
  • HY-19367
    MD-39-AM

    		Others Cardiovascular Disease
    MD-39-AM exhibits antihypertensive, diuretic and saliuretic activities with good in vivo pharmacokinetic characters .
    MD-39-AM
  • HY-155372
    α-Glucosidase-IN-39

    		Glycosidase Metabolic Disease
    α-Glucosidase-IN-39 is a potent inhibitor of α-glucosidase enzyme with an IC50 of 869.06 ppm. α-Glucosidase-IN-39 can used in study antidiabetic .
    α-Glucosidase-IN-39
  • HY-169683
    CDK2-IN-39

    		CDK Cancer
    CDK2-IN-39 (compound 4) is a CDK2 inhibitor .
    CDK2-IN-39
  • HY-P10851
    HVEM(14-39)

    		Apoptosis Inflammation/Immunology Cancer
    HVEM(14-39) is a B- and T-lymphocyte attenuator (BTLA) peptide inhibitor. HVEM (14-39) can be combined with BTLA with a KD of 0.102 μM. HVEM(14-39) enhances the activation and proliferation of T cells by regulating the expression of BTLA and HVEM in T cells, and promotes the transformation of cells into effector memory T cells. HVEM(14-39) inhibits tumor cell proliferation and promotes late apoptosis. HVEM(14-39) has immunomodulatory effects and can be used in the study of cancer .
    HVEM(14-39)
  • HY-103545
    GIP (1-39)

    Gastric inhibitory peptide (1-39) (porcine)

    		 Insulin Receptor Metabolic Disease
    GIP (1-39) (Gastric inhibitory peptide (1-39) (porcine)) is an insulinotropic peptide that stimulats insulin secretion from rat pancreatic islets. GIP (1-39) at 100 nM was able to significantly increase intracellular Ca 2+ concentration ([Ca 2+]i), and capable of enhancing exocytosis .
    GIP (1-39)
  • HY-163587
    PRMT5-IN-39-d3

    		Histone Methyltransferase Cancer
    PRMT5-IN-39-d3 is the deuterated form of PRMT5-IN-39. PRMT5-IN-39-d3 is an orally active PRMT5 inhibitor and can be used for study of cancer .
    PRMT5-IN-39-d3
  • HY-139756
    Antibacterial agent 39

    		Bacterial Infection
    Antibacterial agent 39, an antibacterial agent, significantly lowers MIC value of antibacterial agent Ceftazidime .
    Antibacterial agent 39
  • HY-171038
    STAT3-IN-39

    		STAT Inflammation/Immunology
    STAT3-IN-39 (compound 10K) is an orally active STAT3 inhibitor that exhibits excellent inhibitory activity against STAT3 phosphorylation, with an IC50 of 0.47 μM in NIH-3T3 cells. STAT3-IN-39 inhibits the TGF-β1-induced fibrotic response and blocks the epithelial-mesenchymal transition in A549. STAT3-IN-39 can be utilized in research related to idiopathic pulmonary fibrosis .
    STAT3-IN-39

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: